JP2023520488A5 - - Google Patents

Info

Publication number
JP2023520488A5
JP2023520488A5 JP2022560108A JP2022560108A JP2023520488A5 JP 2023520488 A5 JP2023520488 A5 JP 2023520488A5 JP 2022560108 A JP2022560108 A JP 2022560108A JP 2022560108 A JP2022560108 A JP 2022560108A JP 2023520488 A5 JP2023520488 A5 JP 2023520488A5
Authority
JP
Japan
Prior art keywords
polynucleotide
aav vector
promoter
sequence
reverse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022560108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520488A (ja
JP7785359B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025281 external-priority patent/WO2021202817A1/en
Publication of JP2023520488A publication Critical patent/JP2023520488A/ja
Publication of JP2023520488A5 publication Critical patent/JP2023520488A5/ja
Application granted granted Critical
Publication of JP7785359B2 publication Critical patent/JP7785359B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022560108A 2020-04-01 2021-03-31 Ush1bの処置のための安全性が改善されたデュアルaav-myo7aベクター Active JP7785359B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003774P 2020-04-01 2020-04-01
US63/003,774 2020-04-01
PCT/US2021/025281 WO2021202817A1 (en) 2020-04-01 2021-03-31 Dual aav-myo7a vectors with improved safety for the treatment of ush1b

Publications (3)

Publication Number Publication Date
JP2023520488A JP2023520488A (ja) 2023-05-17
JP2023520488A5 true JP2023520488A5 (enExample) 2024-04-10
JP7785359B2 JP7785359B2 (ja) 2025-12-15

Family

ID=77929961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560108A Active JP7785359B2 (ja) 2020-04-01 2021-03-31 Ush1bの処置のための安全性が改善されたデュアルaav-myo7aベクター

Country Status (8)

Country Link
US (2) US12377169B2 (enExample)
EP (1) EP4126071A4 (enExample)
JP (1) JP7785359B2 (enExample)
CN (1) CN115666658A (enExample)
AU (1) AU2021247172A1 (enExample)
CA (1) CA3174500A1 (enExample)
IL (1) IL295741A (enExample)
WO (1) WO2021202817A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12359221B2 (en) 2017-05-05 2025-07-15 The Regents Of The University Of California Compositions and methods for expressing otoferlin
WO2020093018A1 (en) 2018-11-01 2020-05-07 University Of Florida Research Foundation, Incorporated A codon optimized otoferlin aav dual vector gene therapy
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
TWI896570B (zh) 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
US20240167056A1 (en) * 2022-05-09 2024-05-23 Akouos, Inc. Cell specific gene therapy delivery compositions and methods for treating hearing loss
CN116925239B (zh) * 2023-07-17 2024-10-18 苏州星奥拓维生物技术有限公司 双载体系统表达Otof基因的组合物和方法
WO2025153705A1 (en) * 2024-01-18 2025-07-24 Splicebio, Sl Use of split intein for the treatment of myo7a-associated disease
CN120400250A (zh) * 2024-02-01 2025-08-01 苏州星奥拓维生物技术有限公司 表达myo7a蛋白的双载体系统及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4445701A (en) 2000-03-24 2001-10-03 Centre National De La Recherche Scientifique-Cnrs Multiple human and mouse otoferlin isoforms
EP2434020B1 (en) 2004-01-22 2014-11-05 Dnavec Research Inc. Method of producing Paramyxoviridae viral vectors using a hybrid promoter comprising a cytomegalovirus enhancer and a chicken beta-actin promoter
US8298818B2 (en) 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008088895A2 (en) 2007-01-18 2008-07-24 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
FR2919305B1 (fr) 2007-07-26 2009-09-18 Genethon Ass Loi De 1901 Vecteurs viraux adeno-associes pour l'expression de la dysferline.
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
WO2010062905A2 (en) 2008-11-26 2010-06-03 The Regents Of The University Of California Lateral ventricle cell compositions and use for treating neural degenerative diseases
HUE041571T2 (hu) 2010-04-23 2019-05-28 Univ Florida RAAV-guanilát-cikláz-készítmények és ejárások 1-es típusú Leber-féle veleszületett vakság (LCA1) kezelésére
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CN105209619B (zh) 2013-03-11 2018-10-12 泰莱托恩基金会 miR-204和miR-211及其用途
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
KR102298579B1 (ko) 2013-05-21 2021-09-07 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
US11000597B2 (en) 2015-01-21 2021-05-11 University Of Florida Research Foundation, Incorporated Engineered receptor/ligand system for delivery of therapeutic agents
US10751385B2 (en) 2015-02-20 2020-08-25 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
CA2979120A1 (en) 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
CN107112767B (zh) 2015-06-30 2019-06-07 深圳市大疆创新科技有限公司 充电控制电路、充电装置、充电系统及充电控制方法
AU2016324317A1 (en) 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
CA3007476A1 (en) 2015-12-11 2017-06-15 Massachusetts Eye And Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
EP3393522B1 (en) * 2015-12-22 2021-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
AU2017286623A1 (en) * 2016-06-15 2018-12-20 Oxford University Innovation Limited Dual overlapping adeno-associated viral vector system for expressing ABC4A
WO2018039375A1 (en) 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
MA47820A (fr) 2017-03-10 2020-01-15 Genethon Traitement de la glycogénose de type iii
US12359221B2 (en) 2017-05-05 2025-07-15 The Regents Of The University Of California Compositions and methods for expressing otoferlin
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
CA3094828A1 (en) * 2018-03-23 2019-09-26 Massachusetts Eye And Ear Infirmary Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome
WO2020093018A1 (en) 2018-11-01 2020-05-07 University Of Florida Research Foundation, Incorporated A codon optimized otoferlin aav dual vector gene therapy
CN113924109A (zh) 2019-01-18 2022-01-11 巴斯德研究所 Aav介导的基因疗法恢复耳畸蛋白基因
TWI896570B (zh) 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject

Similar Documents

Publication Publication Date Title
JP2024009857A5 (enExample)
JP2022500066A5 (enExample)
JP2018522529A5 (enExample)
JP2022508182A5 (enExample)
JP2022549380A5 (enExample)
JP2022535749A5 (enExample)
JP2024514956A (ja) 組織標的化された改変aavカプシドおよびその使用方法
JP2022522996A5 (enExample)
JP2020511127A5 (enExample)
JP2020522269A5 (enExample)
JP2017509632A5 (enExample)
JP2022531809A5 (enExample)
JP2022551744A5 (enExample)
AU2017286623A1 (en) Dual overlapping adeno-associated viral vector system for expressing ABC4A
JP2021533805A5 (enExample)
JP2022530095A5 (enExample)
JP2022553406A5 (enExample)
JP2023537980A5 (enExample)
JP2023551873A5 (enExample)
JP2024543001A5 (enExample)
JP2023537358A5 (enExample)
JP2023524414A5 (enExample)
JP2023549124A5 (enExample)
JP2023553005A5 (enExample)
JP2023529371A5 (enExample)